Ichthyosis associated with immune checkpoint blockade therapy: A novel cutaneous immune-related toxicity

Published:August 15, 2022DOI:
      Immune checkpoint blockers (ICBs) have been associated with a variety of dermatologic adverse reactions. Macular rashes, eczematous and lichenoid reactions, vitiligo, psoriasis and pruritus are some of the most frequently observed and well-known cutaneous toxicities.
      • Sibaud V.
      Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy.
      However, skin reactions derived from ICBs have a wide clinical spectrum, leading to a variety of clinical entities. Therefore, clinicians need to be watchful when they encounter skin reactions. We present the first cases of ichthyosis triggered by ICBs, and we describe the clinical characteristics, the therapeutic interventions, and treatment outcomes of this unusual ICB-induced toxicity.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sibaud V.
        Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy.
        Am J Clin Dermatol. 2018; 19: 345-361
        • DiCiovanna J.
        • Robinson-Bostom L.
        Ichthyosis etiology, diagnosis and management.
        Am J Clin Dermatol. 2003; 4: 81-95
        • Thakur V.
        • Malhotra P.
        • Lad D.
        • Chatterjee D.
        • Vinay K.
        • Dogra S.
        Panotinib-induced lamellar ichthyosis-like eruption.
        Int J Dermatol. 2020; 59: e156-e157
        • Rivera N.
        • Boada A.
        • Bielsa M.I.
        • et al.
        Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer.
        JAMA Dermatol. 2017; 153: 1162-1165
        • Fattore D.
        • Panariello L.
        • Annuziata M.C.
        • Fabbrocini G.
        Prurigo nodularis and pembrolizumab: a therapeutic challenge.
        Eur J Cancer. 2019; 110: 8-10